跳至主要内容
临床试验/NCT05823506
NCT05823506招募中不适用

Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction: Randomized Controlled Trial

Saint Petersburg State University, Russia1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2023年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
36
试验地点
1
主要终点
IIEF-5

研究概览

简要总结

The goal of this trial is that using tadalafil plus low-intensity extracorporeal shockwave therapy (li-ESWT) is more effective than using tadalafil alone in improving erection rigidity and sexual function. The efficacy of the combination of li-ESWT and tadalafil has been confirmed by a number of studies, including in patients after radical prostatectomy. However, this method is still not a "first-line" method in young primary patients and its benefits in combination with drugs for these patients are not obvious.

The investigators assume that the combination of tadalafil plus low-intensity extracorporeal shockwave therapy (li-ESWT) will improve the subjective state of patients assessed by points of validated questionnaires and Number of successful intercourse per week.

详细描述

The aim of the study is to test the hypothesis that using tadalafil plus shockwave in primary patient with ED treatment in more effective in improving erection rigidity and sexual function, then using tadalafil alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Age 20 to 45;
  • Married or have had a permanent sex partner for at least 3 months;
  • IIEF-5 questionnaire scores below 20

排除标准

  • History of previous use of PDE-5 inhibitors or fSWT;
  • Patients with diabetes mellitus;
  • Patients after the radical prostatectomy or major pelvic surgery;
  • Patients with a confirmed neurological disease that may have caused the ED (Multiple Sclerosis, Parkinson's Disease, spinal cord injury);
  • Patients with contraindications to the use of PDE-5 inhibitors and/or fSWT;

研究组 & 干预措施

Combination group

Experimental

PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month plus Device BTL-6000 fSWT: 6 sessions with EFD 0,09 mJ/mm2 by 5000 impulses per session in 5 points in corpora cavernosa penis

干预措施: PDE5 inhibitor (tadalafil) (Drug)

Medication group

Active Comparator

PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month

干预措施: PDE5 inhibitor (tadalafil) (Drug)

Combination group

Experimental

PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month plus Device BTL-6000 fSWT: 6 sessions with EFD 0,09 mJ/mm2 by 5000 impulses per session in 5 points in corpora cavernosa penis

干预措施: PDE5 inhibitor (tadalafil) and BTL-6000 fSWT (Combination Product)

结局指标

主要结局

IIEF-5

时间窗: 60 days

IIEF-5 (International Index of Erectile Function-5) is validated erectile function assessment questionnaire. The possible scores for the IIEF-5 range from 5 to 25, with lower values representing poorer sexual function.

次要结局

  • PGI-I(14 days,30 days, 60days.)
  • Likert scale (7-point preferably) satisfaction questionnaire(14 days,30 days, 60days.)
  • Therapy comfort survey(14 days,30 days, 60days.)
  • Number of successful intercourse per week(14 days,30 days, 60days.)

研究者

发起方
Saint Petersburg State University, Russia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gleb Kovalev

The head of outpatient urology department, phD

Saint Petersburg State University, Russia

研究点 (1)

Loading locations...

相似试验